GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (NAS:PCVX) » Definitions » Property, Plant and Equipment

PCVX (Vaxcyte) Property, Plant and Equipment : $249.93 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Property, Plant and Equipment?

Vaxcyte's quarterly net PPE increased from Mar. 2024 ($157.32 Mil) to Jun. 2024 ($203.34 Mil) and increased from Jun. 2024 ($203.34 Mil) to Sep. 2024 ($249.93 Mil).

Vaxcyte's annual net PPE declined from Dec. 2021 ($35.91 Mil) to Dec. 2022 ($31.65 Mil) but then increased from Dec. 2022 ($31.65 Mil) to Dec. 2023 ($145.31 Mil).


Vaxcyte Property, Plant and Equipment Historical Data

The historical data trend for Vaxcyte's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Property, Plant and Equipment Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Property, Plant and Equipment
Get a 7-Day Free Trial 3.39 3.27 35.91 31.65 145.31

Vaxcyte Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.76 145.31 157.32 203.34 249.93

Vaxcyte Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Vaxcyte  (NAS:PCVX) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Vaxcyte Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Vaxcyte's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxcyte Business Description

Industry
Traded in Other Exchanges
Address
825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Executives
Jim Wassil officer: Chief Operating Officer C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Grant Pickering director, officer: President & CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Andrew Guggenhime officer: CFO, CBO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Mikhail Eydelman officer: SVP, Gen Counsel & Corp Sec C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Teri Loxam director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Elvia Cowan officer: See Remarks Section C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Halley E Gilbert director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Jeff Fairman officer: VP, Research C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Paul Sauer officer: SVP Process Dev, Manufacturing C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404
Michael E. Kamarck director C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Carlos V Paya director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Harpreet S. Dhaliwal officer: SVP Cml Mfg & Supply Chain C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Anne S Drapeau director C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110
Jane Wright Mitchell officer: General Counsel C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063